Understanding how certain cancer drugs affect cell death and growth
Identification of critical cellular pathways triggered by mitomycins interstrand crosslinks
['FUNDING_OTHER'] · JOHN JAY COLLEGE OF CRIMINAL JUSTICE · NIH-10896133
This study is looking at how certain cancer-fighting drugs called mitomycins damage cancer cells and stop them from growing, especially when a key protein that helps control cell health isn't working properly, with the goal of finding better ways to treat cancer for patients like you.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHN JAY COLLEGE OF CRIMINAL JUSTICE (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10896133 on ClinicalTrials.gov |
What this research studies
This research investigates how specific anti-cancer drugs, known as mitomycins, create DNA damage that leads to cell death or halts cell growth. The study focuses on understanding the different ways these drugs interact with cancer cells, particularly in cases where a key protein, p53, is not functioning. By examining various forms of mitomycins and their effects on cellular pathways, the research aims to uncover critical mechanisms that could improve cancer treatment strategies. Patients may benefit from insights gained about how these drugs work and how to enhance their effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that are treated with mitomycin-based therapies.
Not a fit: Patients whose cancers are not treated with mitomycins or who do not have a functioning p53 protein may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments by identifying more effective ways to use mitomycins.
How similar studies have performed: Previous research has shown that understanding the mechanisms of DNA damage in cancer cells can lead to significant advancements in treatment strategies.
Where this research is happening
NEW YORK, UNITED STATES
- JOHN JAY COLLEGE OF CRIMINAL JUSTICE — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHAMPEIL, ELISE — JOHN JAY COLLEGE OF CRIMINAL JUSTICE
- Study coordinator: CHAMPEIL, ELISE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents